AI Engines For more Details: Perplexity Kagi Labs You
Antiemetic Effects: Thiethylperazine dimaleate is classified as an antiemetic, which means it helps prevent or relieve nausea and vomiting. It works by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ) of the brain, thereby reducing the signals that trigger vomiting.
Indications: Torecan is typically prescribed for the management of nausea and vomiting caused by various factors, including:
Dosage and Administration: The dosage of Torecan varies depending on the individual's age, weight, and the severity of symptoms. It is usually taken orally as tablets or administered intramuscularly or intravenously in more severe cases. The medication should be taken as directed by a healthcare professional.
Onset and Duration of Action: Torecan typically begins to take effect within 30 to 60 minutes after oral administration. The duration of its antiemetic effects can last for several hours, but the exact duration varies among individuals.
Side Effects: Common side effects of thiethylperazine dimaleate may include:
Precautions: Torecan should be used with caution in individuals who are sensitive to antihistamines or have a history of certain medical conditions, such as glaucoma, urinary retention, or prostatic hypertrophy. It may also impair cognitive and motor functions, so patients should avoid activities requiring mental alertness, such as driving or operating machinery, while taking this medication.
Drug Interactions: Thiethylperazine dimaleate may interact with other medications, including central nervous system depressants such as alcohol, benzodiazepines, and opioids. Patients should inform their healthcare provider about all medications, supplements, or herbal products they are taking to prevent potential interactions.
Contraindications: Torecan is contraindicated in individuals with a known hypersensitivity to the drug or its components. It should also be avoided in patients with severe central nervous system depression, coma, or liver disease.
Pregnancy and Lactation: The safety of thiethylperazine dimaleate during pregnancy and lactation has not been established. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.
Overdose: In case of overdose, symptoms may include excessive sedation, respiratory depression, or cardiovascular effects. Immediate medical attention should be sought if an overdose is suspected.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 2.7 | 0.6 | 3.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.3 | 0.5 | 3.6 |
| Allergies | 4.7 | 2.1 | 1.24 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 4.2 | 5.5 | -0.31 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.7 | 0.5 | 4.4 |
| Ankylosing spondylitis | 3.2 | 1.5 | 1.13 |
| Anorexia Nervosa | 1.2 | 2.4 | -1 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 2.9 | 1.4 | 1.07 |
| Atherosclerosis | 1.8 | 1.8 | 0 |
| Atrial fibrillation | 3.5 | 2.5 | 0.4 |
| Autism | 7.4 | 7.5 | -0.01 |
| Autoimmune Disease | 0.3 | 0.8 | -1.67 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 1.3 | 1.1 | 0.18 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.5 | -0.5 | |
| Carcinoma | 2.6 | 2.3 | 0.13 |
| Celiac Disease | 2.1 | 2.8 | -0.33 |
| Cerebral Palsy | 0.7 | 1.3 | -0.86 |
| Chronic Fatigue Syndrome | 2.8 | 5.8 | -1.07 |
| Chronic Kidney Disease | 2.7 | 2.4 | 0.13 |
| Chronic Lyme | 0.5 | 0.8 | -0.6 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 1.1 | -2.67 |
| Chronic Urticaria (Hives) | 1.4 | -1.4 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 1 | -1.5 |
| Cognitive Function | 3.3 | 0.8 | 3.12 |
| Colorectal Cancer | 5.2 | 2 | 1.6 |
| Constipation | 1.5 | 1.4 | 0.07 |
| Coronary artery disease | 1.5 | 2.5 | -0.67 |
| COVID-19 | 5.3 | 9.1 | -0.72 |
| Crohn's Disease | 6.5 | 5.5 | 0.18 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.3 | -1.3 | |
| deep vein thrombosis | 2 | 1.1 | 0.82 |
| Depression | 7.5 | 8.1 | -0.08 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.6 | 0.9 | -0.5 |
| Endometriosis | 2 | 1.4 | 0.43 |
| Epilepsy | 1.7 | 1.6 | 0.06 |
| erectile dysfunction | 0.9 | 0.3 | 2 |
| Fibromyalgia | 2.1 | 2.4 | -0.14 |
| Functional constipation / chronic idiopathic constipation | 3.9 | 3.5 | 0.11 |
| gallstone disease (gsd) | 2.6 | 0.9 | 1.89 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.9 | 0.33 |
| Generalized anxiety disorder | 1.4 | 1.7 | -0.21 |
| Gout | 0.7 | 0.7 | 0 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.4 | 1.7 | -3.25 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 2.8 | 1.3 | 1.15 |
| Heart Failure | 3 | 2 | 0.5 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.6 | -0.2 |
| hypercholesterolemia (High Cholesterol) | 0.2 | -0.2 | |
| hyperglycemia | 0.6 | 1.4 | -1.33 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3 | 4.8 | -0.6 |
| Hypothyroidism | 0.1 | 0.7 | -6 |
| Hypoxia | 1.7 | 0.9 | 0.89 |
| IgA nephropathy (IgAN) | 1 | 3.8 | -2.8 |
| Inflammatory Bowel Disease | 5 | 7.8 | -0.56 |
| Insomnia | 1.3 | 2.1 | -0.62 |
| Intelligence | 1.2 | 0.6 | 1 |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 4.8 | 4.3 | 0.12 |
| ischemic stroke | 1.7 | 1.1 | 0.55 |
| Liver Cirrhosis | 4.8 | 3.5 | 0.37 |
| Long COVID | 4.9 | 6.7 | -0.37 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | 1.2 | -3 |
| Mast Cell Issues / mastitis | 0.9 | -0.9 | |
| ME/CFS with IBS | 0.5 | 2.1 | -3.2 |
| ME/CFS without IBS | 0.6 | 2 | -2.33 |
| Menopause | 0.2 | 0.6 | -2 |
| Metabolic Syndrome | 6 | 6.5 | -0.08 |
| Mood Disorders | 6.5 | 5.6 | 0.16 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | 0 |
| Multiple Sclerosis | 3.7 | 5.6 | -0.51 |
| Multiple system atrophy (MSA) | 1 | 0.7 | 0.43 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 2.7 | -2.7 | |
| Neuropathy (all types) | 0.2 | 1.7 | -7.5 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.1 | 3.8 | -0.23 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 8.4 | 6.1 | 0.38 |
| obsessive-compulsive disorder | 4.1 | 3.3 | 0.24 |
| Osteoarthritis | 1.6 | 1 | 0.6 |
| Osteoporosis | 1.1 | 1.2 | -0.09 |
| Parkinson's Disease | 5.8 | 5.4 | 0.07 |
| Polycystic ovary syndrome | 5.5 | 2 | 1.75 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.6 | 0.9 | -0.5 |
| Primary sclerosing cholangitis | 0.7 | 3 | -3.29 |
| Psoriasis | 2.4 | 3.6 | -0.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.2 | 3.6 | 0.72 |
| Rosacea | 0.6 | 0.8 | -0.33 |
| Schizophrenia | 3.5 | 2.7 | 0.3 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 1.2 | 2.6 | -1.17 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.2 | 2 |
| Stress / posttraumatic stress disorder | 2.2 | 2.3 | -0.05 |
| Systemic Lupus Erythematosus | 2.6 | 1.6 | 0.63 |
| Tic Disorder | 0.9 | 1.8 | -1 |
| Tourette syndrome | 0.7 | 0.3 | 1.33 |
| Type 1 Diabetes | 2.8 | 2.8 | 0 |
| Type 2 Diabetes | 7.1 | 6.5 | 0.09 |
| Ulcerative colitis | 3.2 | 6.9 | -1.16 |
| Unhealthy Ageing | 4.2 | 2.3 | 0.83 |
| Vitiligo | 2.2 | 1.4 | 0.57 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
